LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
36.71
+2.71 (7.97%)
At close: Oct 15, 2026, 4:00 PM EDT
36.69
-0.02 (-0.05%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Company Description
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
LB Pharmaceuticals Inc
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 11, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Heather Turner |
Contact Details
Address: One Pennsylvania Plaza, Suite 1025 New York, New York 10119 United States | |
| Phone | 212 605 0300 |
| Website | lbpharma.us |
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1691082 |
| CUSIP Number | 50180M108 |
| ISIN Number | US50180M1080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Heather D. Turner Esq., J.D. | Chief Executive Officer and Director |
| Gad Soffer | Chief Operating and Business Officer |
| Joseph M. Miller CPA | Chief Financial Officer |
| Minako Pazdera J.D., Ph.D. | General Counsel |
| Lindsay Beaupre | Senior Vice President of People and Culture |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations |
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs |
| Ellen Rose | Senior Vice President of Corporate Affairs |
| Kaya Pai Panandiker Kamlesh | Chief Commercial Officer |
| Christopher Zergebel | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | SCHEDULE 13G/A | Filing |
| Oct 5, 2026 | EFFECT | Notice of Effectiveness |
| Oct 1, 2026 | POS AM | Post-Effective amendments for registration statement |
| Oct 1, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Sep 15, 2026 | 424B3 | Prospectus |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 3, 2026 | 424B3 | Prospectus |
| Sep 3, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 11, 2026 | 424B3 | Prospectus |